Sanofi R&D Boss Thinks His Team is Ready to Survive Without Besties Regeneron and Alnylam

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-sanofi.jpg" NAME"Sanofi R&D Boss Thinks His Team is Ready to Survive Without Besties Regeneron and Alnylam" ALT"Sanofi R&D Boss Thinks His Team is Ready to Survive Without Besties Regeneron…

Continue ReadingSanofi R&D Boss Thinks His Team is Ready to Survive Without Besties Regeneron and Alnylam

New Kid on the Block Provention Bio Snags 2 Clinic-Ready Immune Compounds From Johnson & Johnson

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x600-deal.jpg" NAME"New Kid on the Block Provention Bio Snags 2 Clinic-Ready Immune Compounds From Johnson & Johnson" ALT"New Kid on the Block Provention Bio Snags 2 Clinic-Ready Immune Compounds…

Continue ReadingNew Kid on the Block Provention Bio Snags 2 Clinic-Ready Immune Compounds From Johnson & Johnson

Famed Genomics Pioneer's Synthetic Genomics Hit With Gender Discrimination Lawsuit by Former VP

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-stocks2.jpg" NAME"Famed Genomics Pioneer's Synthetic Genomics Hit With Gender Discrimination Lawsuit by Former VP" ALT"Famed Genomics Pioneer's Synthetic Genomics Hit With Gender Discrimination Lawsuit by Former VP"September 21, 2017By…

Continue ReadingFamed Genomics Pioneer's Synthetic Genomics Hit With Gender Discrimination Lawsuit by Former VP

Alnylam Stock Catapults as Genetic Disease Drug Meets All Phase III Goals

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x408-ceo-alnylam-john-maraganore.jpg" NAME"Alnylam Stock Catapults as Genetic Disease Drug Meets All Phase III Goals" ALT"Alnylam Stock Catapults as Genetic Disease Drug Meets All Phase III Goals"September 20, 2017By Alex Keown<...…

Continue ReadingAlnylam Stock Catapults as Genetic Disease Drug Meets All Phase III Goals